Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $16K fell 99.9% year over year, ahead of the -109.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 99.9% from the prior quarter.

Context

  • Financing cash flow amounted to 19.9% of revenue in FY2025, up 16.0 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -99.9% holds above the trailing-twelve-month pace of -109.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16K-99.9% QoQ
Last fiscal yearDec 2025
$13.38M+147.0% YoY
LTMMar 2026
-$1.8M-109.8% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.9%——
1 year+147.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
13.38M USD
Year-over-year change
+147.0%
4-year CAGR
-27.3%

Financing Cash Flow vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -109.8% is the lowest of 10, against a peer median of -17.1%.
  • Financing cash flow amounts to 4.0% of revenue for ARCT, versus a peer median of 12.2%.
ARCT Competitors
Financing Cash Flow for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$165.71M USD+3328.0%-52.2%253.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026$106.87M USD-1.1%——
NVAXNovavax, Inc.LTM Mar 2026$72.47M USD-70.7%-56.0%12.2%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$52.98M USD-17.1%-13.5%—
VALNValneva SELTM Mar 2026€33.89M EUR+4.1%—21.7%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$25.14M USD+10830.9%——
ABUSArbutus Biopharma CorporationLTM Mar 2026$14.56M USD-52.0%-43.6%7.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$1.8M USD-109.8%—4.0%
PRQRProQR Therapeutics N.V.LTM Mar 2026€1.63M EUR-102.3%-61.5%12.2%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$155K USD-99.9%-90.2%—
SLNSilence Therapeutics plcLTM Mar 2026$911.01 USD—-93.4%0.1%
Peer median (excluding ARCT) —-17.1%-56.0%12.2%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
Deferred Income Tax00000
Stock-Based Compensation28.92M30.61M34.65M37.99M25.41M
Change in Working Capital32.63M(12.56M)7.38M(20.81M)(39.2M)
Accounts Receivables(1.24M)603K(29.3M)28.09M(1.59M)
Inventory00000
Accounts Payables(769K)(3.11M)(2.24M)1.92M(2.96M)
Other Working Capital34.64M(10.05M)38.92M(50.81M)(34.65M)
Other Non-Cash Items5.9M3.06M(33.36M)471K2.28M
Operating Cash Flow(135.04M)31.99M(18.1M)(59.75M)(74.27M)
Capital Expenditures(3.41M)(7.73M)(2.9M)(648K)(230K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(3.41M)(7.73M)(2.9M)(648K)(230K)
Debt Repayment46.6M(5M)(27.36M)00
Common Stock Issued515K411K609K682K13.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities902K1.73M2.67M4.74M0
Financing Cash Flow48.02M(2.86M)(24.09M)5.42M13.38M
Effect of Forex Changes00000
Net Change in Cash(90.43M)21.41M(45.09M)(54.98M)(61.12M)
Free Cash Flow(138.45M)24.27M(21M)(60.4M)(74.27M)

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.